SCHEMBL24316647

SCHEMBL24316647

O=c1c(Br)cnc2ccc(F)cn12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
ADORA2A P29274 4/20 0.39
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
FADS1 O60427 2/20 0.36
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
JAK2 O60674 6/20 0.35
JAK3 P52333 6/20 0.35
JAK1 P23458 5/20 0.35
FLT3 P36888 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24316522 0.79 ALDH1A1 (0.48) KDM4EALDH1A1HPGDADORA2APRMT5
SCHEMBL24316735 0.74 CYP11B2 (0.41) KDM4EALDH1A1HPGDADORA2AJAK2
SCHEMBL28417731 0.74 FLT3 (0.49) ADORA2APRMT5WDR77JAK2JAK3
SCHEMBL17383671 0.72 PIK3CA (0.46) KDM4EALDH1A1HPGDADORA2APOLB
SCHEMBL21273200 0.71 ADORA3 (0.50) KDM4EALDH1A1HPGDNPC1POLB
SCHEMBL1353156 0.71 TGFBR1 (0.50) KDM4EALDH1A1HPGDADORA2APRMT5
SCHEMBL1355409 0.71 ADORA2A (0.40) KDM4EALDH1A1HPGDADORA2APRMT5
SCHEMBL14041215 0.71 TGFBR1 (0.43) ALDH1A1HPGDADORA2AFLT3
SCHEMBL24316792 0.70 TGFBR1 (0.43) KDM4EALDH1A1HPGDADORA2ANPC1
SCHEMBL3787763 0.70 ADORA2A (0.40) KDM4EALDH1A1HPGDADORA2APRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092774-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2024-03-21 US disclosed
EP-4214198-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-07-26 EP disclosed
CN-116323582-A Heteroaromatic ring compounds and uses thereof 和记黄埔医药(上海)有限公司 2023-06-23 CN disclosed
WO-2022057895-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-03-24 WO disclosed
WO-2022057895-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092774-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF CYP2D6, CYP3A7, CYP2F1 KDM4E 4085/4885ALDH1A1 169/4885HPGD 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.